All In Biotech

Drug Trial Radar · NCT05998759

Telitacicept for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

A Randomized, Double-blind Placebo-controlled Study of Recombinant Human B Lymphocyte Stimulating Factor Receptor-Fc Fusion Protein for the Treatment of Connective Tissue Disease-associated Thrombocytopenia

Last checked: Nov 19, 2026Latest source record: May 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 296 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

296

Planned (sponsor's estimate)

Start

Dec 2, 2023

Primary completion

Dec 2025

Study completion Dec 2025

Sponsor

Lead sponsor
Beijing HospitalGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
The First Affiliated Hospital of Anhui Medical University; The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial); Peking University People's Hospital; Peking University Third Hospital; First Affiliated Hospital, Sun Yat-Sen University; Guangdong Provincial People's Hospital; The First Affiliated Hospital of Zhengzhou University; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Second Xiangya Hospital of Central South University; Xiangya Hospital of Central South University; The Affiliated Hospital of Inner Mongolia Medical University; First Hospital of China Medical University; Shandong Provincial Hospital; Changhai Hospital; RenJi Hospital; Shanxi Bethune Hospital; West China Hospital; Institute of Hematology & Blood Diseases Hospital, China; Tianjin First Central Hospital; Tianjin Medical University General Hospital; People's Hospital of Xinjiang Uygur Autonomous Region; The First People's Hospital of Yunnan
First posted
Aug 21, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the efficacy and safety of Telitacicept for the treatment of connective tissue disease-associated thrombocytopenia.

Conditions

  • Connective Tissue Diseases
  • Thrombocytopenia

Interventions

  • TelitaciceptBiological

    subcutaneous telitacicept 160 mg weekly for 24 weeks.

  • PlaceboDrug

    subcutaneous placebo weekly for 24 weeks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response (CR + PR) rateTime frame: at week 24

Locations

23 sites in 1 country. Site status is shown where the registry gives one.

  • The First Affiliated Hospital of Anhui Medical College

    Hefei, Anhui, China · Recruiting

  • The First Affiliated Hospital of China University of Science and Technology (Anhui Provincial)

    Hefei, Anhui, China · Recruiting

  • Beijing Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University People's Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China · Recruiting

  • First Affiliated Hospital, Sun Yat-Sen University

    Guangzhou, Guangdong, China · Recruiting

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China · Recruiting

  • Wuhan Union Hospital, China

    Wuhan, Hubei, China · Recruiting

  • Second Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • Xiangya Hospital of Central South University

    Changsha, Hunan, China · Recruiting

  • The Affiliated Hospital of Inner Mongolia Medical University

    Hohhot, Inner Mongolia, China · Recruiting

  • First Hospital of China Medical University

    Shenyang, Liaoning, China · Recruiting

  • Shandong Provincial Hospital

    Jinan, Shandong, China · Recruiting

  • Changhai Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • RenJi Hospital

    Shanghai, Shanghai Municipality, China · Recruiting

  • Shanxi Bethune Hospital

    Taiyuan, Shanxi, China · Recruiting

  • West China Hospital

    Chengdu, Sichuan, China · Recruiting

  • Institute of Hematology & Blood Diseases Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Tianjin First Central Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • Tianjin Medical University General Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

  • People's Hospital of Xinjiang Uygur Autonomous Region

    Ürümqi, Xinjiang Uygur Autonomous Region, China · Recruiting

  • The First People's Hospital of Yunnan

    Kunming, Yunnan, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.